Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow
Bärbel Huber, Claus Keller, Martin Jenkins, Abid Raza, Magnus Aurivillius, Bärbel Huber, Claus Keller, Martin Jenkins, Abid Raza, Magnus Aurivillius
Abstract
Background and aims: Low peak inspiratory flow (PIF) is common following severe exacerbations of chronic obstructive pulmonary disease (COPD). Patients with COPD and low PIF may be at risk of suboptimal delivery of inhaled therapies to the airways, especially when using devices such as dry powder inhalers (DPIs), which require greater inspiratory effort than metered dose inhalers (MDIs). We report the results from a 2-week crossover study evaluating the effects of inhaled dual therapy with budesonide/formoterol fumarate dihydrate with an MDI with a spacer versus a DPI in patients with COPD and low PIF.
Methods: This randomized, open-label, two-period (each 1 week in duration) crossover efficacy and safety study included patients with severe-to-very severe COPD and PIF < 50 L/min (NCT04078126). Patients were randomized 1:1 to twice-daily budesonide/formoterol fumarate dihydrate MDI (BFF MDI) 320/10 µg with a spacer for 1 week followed by twice-daily budesonide/formoterol fumarate dihydrate DPI (BUD/FORM DPI) 320/9 µg for 1 week, or the inverse. The primary endpoint was peak change from baseline in forced expiratory volume in 1 s (FEV1) within 4 h post-dose following 1 week of treatment. Other assessments included pre-dose lung function, pharmacokinetics, and safety, as assessed by adverse events.
Results: The modified intention-to-treat analysis set comprised 30 patients (mean age: 66.9 years; mean baseline FEV1: 766 mL; mean COPD assessment test score: 22.20). Following 1 week of treatment, both BFF MDI and BUD/FORM DPI improved mean [95% confidence interval (CI)] peak FEV1 4 h post-dose [256 (190, 322) mL and 274 (208, 340) mL, respectively]. No clinically meaningful difference between treatments was observed for any lung function endpoint. There were no unexpected safety findings.
Conclusion: Dual therapy with BFF MDI and with BUD/FORM DPI led to improvements in lung function in patients with severe-to-very severe COPD and low PIF.
Keywords: budesonide; chronic obstructive pulmonary disease; dry powder inhaler; formoterol fumarate dihydrate; inhaled dual therapy; metered dose inhaler; peak inspiratory flow.
Conflict of interest statement
Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: B.H. is an employee of Inamed Gmbh (part of Nuvisan Gmbh), which was contracted by AstraZeneca for this study. C.K. has a lung and bronchial medicine practice, including a study center in Frankfurt am Main, Germany and was contracted by AstraZeneca as a consultant research physician for this study. A.R. is an employee of Medsearch UK Limited and was contracted by AstraZeneca as a consultant research physician for this study. M.A. and M.J. are employees of AstraZeneca and own stock or stock options in the company.
Figures
References
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021. Report. .
- Sharma G, Mahler DA, Mayorga VM, et al.. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis 2017; 4: 217–224.
- Loh CH, Peters SP, Lovings TM, et al.. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc 2017; 14: 1305–1311.
- Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2017; 14: 1103–1107.
- Feddah MR, Brown KF, Gipps EM, et al.. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharmaceut Sci 2000; 3: 318–324.
- Altman P, Wehbe L, Dederichs J, et al.. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med 2018; 18: 100.
- Vincken W, Levy ML, Scullion J, et al.. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res 2018; 4: 00065-02018.
- Dorinsky P, DePetrillo P, DeAngelis K, et al.. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate dihydrate metered dose inhaler administered with and without a spacer: results of a phase I, randomized, crossover trial in healthy adults. Clin Ther 2020; 42: 634–648.
- Gillen M, Forte P, Svensson JO, et al.. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler. Pulm Pharmacol Ther 2018; 52: 7–17.
- Dunn LJ, Kerwin EM, DeAngelis K, et al.. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Pulm Pharmacol Ther 2020; 60: 101873.
- Ferguson GT, Rabe KF, Martinez FJ, et al.. KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD. Eur Respir J 2018; 52(Suppl. 62): OA1661.
- Ferguson G, Rabe K, Bourne E, et al.. 12-hour lung function assessment of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler delivered by co-suspension delivery technology in patients with COPD. Presented at the American Thoracic Society 2019 International Conference (May 17–22; Dallas, TX, USA), Poster number 540.
- Maes A, DePetrillo P, Siddiqui S, et al.. Pharmacokinetics of co-suspension delivery technology budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate (BFF MDI) fixed-dose combinations compared with an active control: a Phase 1, randomized, single dose, crossover study in healthy adults. Clin Pharmacol Drug Dev 2019; 8: 223–233.
- Samarghandi A, Ioachimescu OC, Qayyum R. Association between peak inspiratory flow rate and hand grip muscle strength in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. PLOS ONE 2020; 15: e0227737.
- Bohannon RW. Grip strength: an indispensable biomarker for older adults. Clin Interv Aging 2019; 14: 1681–1691.
Source: PubMed